| Medical and Health Sciences | Lifetime | 315 | US 174 | 99.99 |
| Medical and Health Sciences | 2021-2025 | 1 | US 1 | 100.00 |
| Cardiology and Cardiovascular Medicine | Lifetime | 71 | US 39 | 99.94 |
| Endocrinology, Diabetes and Metabolism | Lifetime | 70 | US 39 | 99.78 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 1 | US 1 | 100.00 |
| Endocrinology, Diabetes and Metabolism | 2021-2025 | 3 | US 1 | 99.98 |
| Surgery | 2021-2025 | 174 | US 71 | 98.96 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 199 | US 65 | 98.52 |
| Medical Physiology | 2021-2025 | 349 | US 126 | 95.26 |
| Hematology | 2021-2025 | 213 | US 103 | 92.82 |
| Epidemiology | 2021-2025 | 918 | US 332 | 90.63 |
| Cardiovascular Function and Risk Factors | Lifetime | 23 | US 17 | 99.93 |
| Diabetes Treatment and Management | Lifetime | 16 | US 9 | 99.86 |
| Heart Failure Treatment and Management | Lifetime | 20 | US 12 | 99.92 |
| Cardiac pacing and defibrillation studies | Lifetime | 40 | US 23 | 99.80 |
| Potassium and Related Disorders | Lifetime | 8 | US 7 | 99.78 |
| Pancreatic function and diabetes | Lifetime | 149 | US 77 | 99.41 |
| Medication Adherence and Compliance | Lifetime | 31 | US 24 | 99.15 |
| Mechanical Circulatory Support Devices | Lifetime | 106 | US 65 | 99.32 |
| Health Systems, Economic Evaluations, Quality of Life | Lifetime | 519 | US 245 | 98.70 |
| Erythropoietin and Anemia Treatment | Lifetime | 82 | US 36 | 98.44 |
| Metabolism, Diabetes, and Cancer | Lifetime | 458 | US 211 | 98.32 |
| Cardiac Structural Anomalies and Repair | Lifetime | 530 | US 315 | 98.47 |
| Blood Pressure and Hypertension Studies | Lifetime | 893 | US 365 | 97.64 |
| Diabetes Management and Research | Lifetime | 828 | US 348 | 97.43 |
| Electrolyte and hormonal disorders | Lifetime | 373 | US 170 | 96.61 |
| Cardiovascular Disease and Adiposity | Lifetime | 783 | US 369 | 96.37 |
| Heart rate and cardiovascular health | Lifetime | 106 | US 42 | 92.79 |
| Apelin-related biomedical research | Lifetime | 628 | US 184 | 87.73 |
| Cardiovascular Function and Risk Factors | 2021-2025 | 1 | US 1 | 99.99 |
| Diabetes Treatment and Management | 2021-2025 | 1 | US 1 | 99.98 |
| Cardiac pacing and defibrillation studies | 2021-2025 | 1 | US 1 | 99.96 |
| Heart Failure Treatment and Management | 2021-2025 | 1 | US 1 | 99.99 |
| Pancreatic function and diabetes | 2021-2025 | 2 | US 1 | 99.92 |
| Potassium and Related Disorders | 2021-2025 | 2 | US 1 | 99.86 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 67 | US 17 | 98.96 |
| Metabolism, Diabetes, and Cancer | 2021-2025 | 21 | US 12 | 99.30 |
| Erythropoietin and Anemia Treatment | 2021-2025 | 8 | US 5 | 99.05 |
| Medication Adherence and Compliance | 2021-2025 | 19 | US 9 | 96.94 |
| Cardiac Valve Diseases and Treatments | 2021-2025 | 279 | US 119 | 98.11 |
| Electrolyte and hormonal disorders | 2021-2025 | 30 | US 9 | 96.33 |
| Diabetes Management and Research | 2021-2025 | 185 | US 99 | 97.42 |
| Hormonal Regulation and Hypertension | 2021-2025 | 85 | US 26 | 96.25 |
| Apelin-related biomedical research | 2021-2025 | 12 | US 2 | 92.40 |
| Chronic Kidney Disease and Diabetes | 2021-2025 | 159 | US 57 | 95.99 |
| Blood Pressure and Hypertension Studies | 2021-2025 | 275 | US 108 | 95.54 |
| Iron Metabolism and Disorders | 2021-2025 | 134 | US 52 | 94.71 |
| Diet and metabolism studies | 2021-2025 | 672 | US 202 | 94.14 |
| Cardiac Structural Anomalies and Repair | 2021-2025 | 453 | US 211 | 94.98 |
| Cardiac electrophysiology and arrhythmias | 2021-2025 | 579 | US 154 | 92.95 |
| Neuroendocrine Tumor Research Advances | 2021-2025 | 485 | US 118 | 91.45 |
| Cardiac Arrhythmias and Treatments | 2021-2025 | 895 | US 239 | 93.41 |
| Acute Myocardial Infarction Research | 2021-2025 | 666 | US 158 | 92.49 |
| Heart rate and cardiovascular health | 2021-2025 | 15 | US 5 | 88.09 |
| Cardiovascular Disease and Adiposity | 2021-2025 | 508 | US 127 | 87.25 |
| Cardiovascular and exercise physiology | 2021-2025 | 509 | US 83 | 91.04 |
| Chemotherapy-induced cardiotoxicity and mitigation | 2021-2025 | 458 | US 134 | 79.19 |
| Cardiovascular Syncope and Autonomic Disorders | 2021-2025 | 441 | US 143 | 77.44 |
| Pharmacology and Obesity Treatment | 2021-2025 | 402 | US 179 | 75.17 |
| GDF15 and Related Biomarkers | 2021-2025 | 535 | US 141 | 56.65 |